These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation in Non-small Cell Lung Cancer]. Liu X; Zhong D Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):583-589. PubMed ID: 31526463 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer with Rare Mutation]. Li T; Li J Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):19-24. PubMed ID: 33478186 [TBL] [Abstract][Full Text] [Related]
10. A BRAF new world. Frisone D; Friedlaender A; Malapelle U; Banna G; Addeo A Crit Rev Oncol Hematol; 2020 Aug; 152():103008. PubMed ID: 32485528 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792 [TBL] [Abstract][Full Text] [Related]
13. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512 [TBL] [Abstract][Full Text] [Related]
14. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Kobayashi M; Sonobe M; Takahashi T; Yoshizawa A; Ishikawa M; Kikuchi R; Okubo K; Huang CL; Date H Anticancer Res; 2011 Dec; 31(12):4619-23. PubMed ID: 22199339 [TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer. Goldman JM; Gray JE Cancer Genet; 2015 Jun; 208(6):351-4. PubMed ID: 26066373 [TBL] [Abstract][Full Text] [Related]
16. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495 [TBL] [Abstract][Full Text] [Related]
17. BRAF-mutations in non-small cell lung cancer. Brustugun OT; Khattak AM; Trømborg AK; Beigi M; Beiske K; Lund-Iversen M; Helland Å Lung Cancer; 2014 Apr; 84(1):36-8. PubMed ID: 24552757 [TBL] [Abstract][Full Text] [Related]
18. [Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors]. Kang X; Zhu N; Song X Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):711-714. PubMed ID: 27760604 [TBL] [Abstract][Full Text] [Related]
19. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Peng S; Sen B; Mazumdar T; Byers LA; Diao L; Wang J; Tong P; Giri U; Heymach JV; Kadara HN; Johnson FM Oncotarget; 2016 Jan; 7(1):565-79. PubMed ID: 26623721 [TBL] [Abstract][Full Text] [Related]
20. Sensitive genotyping of somatic mutations in the EGFR, KRAS, PIK3CA, BRAF genes from NSCLC patients using hydrogel biochips. Emelyanova M; Arkhipova K; Mazurenko N; Chudinov A; Demidova I; Zborovskaya I; Lyubchenko L; Zasedatelev A; Nasedkina T Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):255-65. PubMed ID: 25153497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]